Combined oral contraceptives and liver cancer

A multi‐national, hospital‐based, case‐control study was conducted to evaluate the possible relationships of steroid contraceptives to 6 neoplasms. Based on data from 122 newly diagnosed cases of primary liver cancer and 802 matched controls, the relative risk of liver cancer in women who had ever u...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramiro Molina, Luis Martinez, Oriana Salas, Aifredo Dabancens, Tao Yun, Chen Zhi‐Heng, Hu Yong‐Wei, Alvaro Cuadros, Nubia Aristizabal, Baruch Modan, Elaine Ron, Esther Alfandary, J. G. Mati, Patrick Kenya, Alfred Kungu, D. Gatei, Patrick A. Ibeziako, A. A. Abioye, T. A. Junaid, Patrick U. Aghadiuno, Ruben A. Apelo, Julietta R. De LaCruz, Jose Baens, Benjamin D. Canlas, Suporn Silpisornkosol, Tieng Pardthaisong, Boonlong Sivasomboom, Choti Theetranont, Banpot Boosiri, Supawat Chutivongse, Pramuan Virutamasen, Chansuda Wongsrichanalai, Sermsri Sindhvananda, Suporn Koetsawang, Duangdao Rachawat, Orawan Kiriwat, Nivat Chantarakul, P. P. Anthony, David B. Thomas, Janet L. Stanford, Roberta M. Ray, Elizabeth A. Noonan, Susan Holck
Other Authors: Facultad de Medicina de la Universidad de Chile
Format: Article
Published: 2018
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/15733
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
Description
Summary:A multi‐national, hospital‐based, case‐control study was conducted to evaluate the possible relationships of steroid contraceptives to 6 neoplasms. Based on data from 122 newly diagnosed cases of primary liver cancer and 802 matched controls, the relative risk of liver cancer in women who had ever used combined oral contraceptives was estimated to be 0.71 (95% Cl 0.4–1.2). No consistent trend in risk with months of use or time since first or last use was observed. Separate analyses also revealed no association between use of combined oral contraceptives and hepatocellular carcinoma (RR = 0.60) or cholangiocarcinoma (RR = 1.22). Most women in this study came from areas in which hepatitis B is endemic and rates of liver cancer are relatively high, and in most cases use of oral contraceptives was of short duration. These results provide no evidence that short‐term use of oral contraceptives enhances risk of liver cancer in countries where the determinants of this disease are similar to those observed in the countries where this study was conducted. Copyright © 1989 Wiley‐Liss, Inc., A Wiley Company